VEA
AKBA icon

Virtus ETF Advisers’s Akebia Therapeutics AKBA Stock Holding History

Virtus ETF Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$428K Buy
+308,000
New +$423K 0.2% 130
2022
Q2 		– Sell
-65,149
Closed -$47K – 437
2022
Q1 		$47K Sell
65,149
-3,866
-6% -$8.27K 0.02% 365
2021
Q4 		$156K Buy
69,015
+10,772
+18% +$29.4K 0.06% 337
2021
Q3 		$168K Sell
58,243
-3,041
-5% -$8.68K 0.07% 313
2021
Q2 		$232K Sell
61,284
-33,148
-35% -$112K 0.1% 237
2021
Q1 		$320K Buy
94,432
+1,661
+2% +$5.98K 0.14% 228
2020
Q4 		$260K Buy
92,771
+65,225
+237% +$190K 0.11% 298
2020
Q3 		$69K Sell
27,546
-3,747
-12% -$32.9K 0.04% 322
2020
Q2 		$425K Sell
31,293
-24,977
-44% -$258K 0.2% 176
2020
Q1 		$427K Sell
56,270
-8,206
-13% -$63.8K 0.18% 190
2019
Q4 		$407K Buy
64,476
+2,846
+5% +$13.5K 0.07% 247
2019
Q3 		$242K Sell
61,630
-3,433
-5% -$14.7K 0.05% 219
2019
Q2 		$315K Buy
65,063
+31,549
+94% +$179K 0.07% 201
2019
Q1 		$274K Sell
33,514
-4,669
-12% -$32K 0.58% 66
2018
Q4 		$211K Sell
38,183
-3,854
-9% -$30.2K 0.04% 175
2018
Q3 		$371K Sell
42,037
-30,371
-42% -$272K 0.04% 173
2018
Q2 		$723K Buy
72,408
+21,946
+43% +$220K 0.64% 90
2018
Q1 		$481K Buy
50,462
+27,003
+115% +$378K 0.42% 112
2017
Q4 		$349K Buy
23,459
+440
+2% +$7.3K 0.44% 88
2017
Q3 		$453K Buy
23,019
+2,106
+10% +$32.4K 0.06% 97
2017
Q2 		$301K Buy
+20,913
New +$265K 0.04% 123
2016
Q4 		– Sell
-29,590
Closed -$268K – 178
2016
Q3 		$268K Hold
29,590
– – 0.13% 116
2016
Q2 		$221K Buy
29,590
+8,160
+38% +$71.2K 0.16% 124
2016
Q1 		$193K Buy
+21,430
New +$174K 0.27% 91

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Virtus ETF Advisers's AKBA Position: Q1 2026 in Review

Virtus ETF Advisers opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 308,000 shares worth $428K. The stake represents 0.2% of the portfolio and ranks #130 among its holdings. This is a return to the name: Virtus ETF Advisers previously reported a position in AKBA as recently as Q1 2022.

Virtus ETF Advisers first reported a position in AKBA in Q1 2016 and has held it in 24 quarters since. The position peaked at $723K in Q2 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Virtus ETF Advisers held 308,000 shares of Akebia Therapeutics worth $428K as of Q1 2026.
  • Akebia Therapeutics was a new Virtus ETF Advisers position in Q1 2026.
  • Akebia Therapeutics made up 0.2% of Virtus ETF Advisers's portfolio in Q1 2026, its #130 holding.
  • Virtus ETF Advisers first reported a position in Akebia Therapeutics in Q1 2016 and has held it in 24 quarters since.
  • Virtus ETF Advisers's Akebia Therapeutics position peaked at $723K in Q2 2018.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.